The earnings call highlighted strong revenue and profit growth across various business segments, consistent profitability, and successful dividend and share buyback programs. However, some product lines underperformed, and trade uncertainties remain a concern. Despite these challenges, the overall performance and growth initiatives present a positive outlook.

Company Guidance

During the BioSyent Inc. Q2 and First Half 2025 Results Presentation, President and CEO René C. Goehrum highlighted strong financial performance with total company revenue just over $10 million for the quarter, reflecting a 14% growth compared to the previous year. Canadian Pharma achieved a record quarter with sales of $9.3 million, a 9% year-over-year increase. The company's EBITDA reached just under $2.8 million, growing by 35%, and NIAT exceeded $2 million, up 28% from the previous year, with EBITDA and NIAT margins at 27% and 20%, respectively. On a six-month basis, sales rose by 27% to over $21 million, driven by growth across Canadian Pharmaceutical, International Pharma, and Legacy business segments. EBITDA increased by 40% to nearly $6 million, while NIAT grew by 30% to over $4.3 million, with corresponding margins of 28% and 21%. The presentation also noted an EPS of $0.18 for Q2 2025, contributing to a trailing-12 month EPS of $0.72. BioSyent continued its share buyback program, repurchasing 19,500 shares year-to-date, and declared a dividend of $0.05 for September, marking an 11% increase over the previous year's dividend. The company maintained a strong cash position with $27 million as of June 30, 2025, and reported a 23% return on equity.

Strong Revenue Growth

Total company revenue was just over $10 million, representing a 14% growth compared to the previous year, with Canadian Pharma having a record quarter.

EBITDA and NIAT Growth

EBITDA was just under $2.8 million, a 35% growth year-over-year, and NIAT was over $2 million, showing a 28% growth.

Canadian Pharma Performance

Canadian Pharma sales reached $9.3 million, up 9% from the previous year, with strong performances from FeraMAX and Tibella.

Dividend Increase

An 11% increase in dividend payment over 2024 was announced, with dividends being paid in March, June, and September.

FeraMAX Brand Success

FeraMAX continues to be the #1 recommended iron supplement among Canadian healthcare professionals, contributing significantly to revenue growth.

Consistent Profitability

The second quarter of 2025 marked the 60th consecutive profitable quarter since 2010.

Share Buyback and Dividend Program

Since the fourth quarter of 2018, the company has bought back $23 million worth of shares and initiated a dividend program returning $6.2 million to shareholders.

Biosyent (TSE:RX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:RX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 13, 2025	2025 (Q3)	- / -	0.2	―	―	―
Aug 21, 2025	2025 (Q2)	- / 0.18	0.13	38.46% (+0.05)	―	―
May 15, 2025	2025 (Q1)	- / 0.20	0.15	33.33% (+0.05)	―	―
Mar 13, 2025	2024 (Q4)	0.15 / 0.14	0.12	16.67% (+0.02)	―	―
Nov 20, 2024	2024 (Q3)	0.14 / 0.20	0.2	0.00% (0.00)	―	―
Aug 26, 2024	2024 (Q2)	0.13 / 0.13	0.12	8.33% (+0.01)	―	―
May 16, 2024	2024 (Q1)	0.08 / 0.15	0.1	50.00% (+0.05)	―	―
Mar 13, 2024	2023 (Q4)	0.17 / 0.12	0.09	33.33% (+0.03)	―	―
Nov 16, 2023	2023 (Q3)	0.10 / 0.20	0.116	72.41% (+0.08)	―	―
Aug 22, 2023	2023 (Q2)	0.12 / 0.12	0.1	20.00% (+0.02)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:RX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 21, 2025	C$11.54	C$11.96	+3.64%
May 15, 2025	C$10.68	C$11.65	+9.08%
Mar 13, 2025	C$10.71	C$11.11	+3.73%
Nov 20, 2024	C$10.73	C$11.11	+3.54%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biosyent Inc (TSE:RX) report earnings?

Biosyent Inc (TSE:RX) is schdueled to report earning on Nov 13, 2025, TBA (Confirmed).

What is Biosyent Inc (TSE:RX) earnings time?

Biosyent Inc (TSE:RX) earnings time is at Nov 13, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:RX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing